Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 subcutaneous versus intravenous plus XELOX as first-line treatment for unresectable advanced or metastatic gastric/GEJ adenocarcinoma
CTR20260795Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Started Mar 2026; status: active.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20260795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260795.